风湿性多肌痛与巨细胞动脉炎达标治疗策略的证据:一项系统文献综述
该研究在Medline、EMBASE、Cochrane Library、clinicaltrials.gov及EULAR/ACR摘要数据库进行系统文献检索,筛选出76篇文献(31项随机对照试验、8项随机对照试验亚组或探索性分析及37项非随机干预性研究)。未发现比较达标治疗策略与标准治疗的研究,提示该领域存在证据空白,为国际工作组制定达标治疗推荐提供依据。
要点
- 未检索到比较达标治疗策略与标准治疗的随机对照试验或非随机干预性研究。
- 风湿性多肌痛随机对照试验中最常报告治疗相关结局(占90.9%),尤其是累积糖皮质激素剂量和减量。
- 巨细胞动脉炎随机对照试验中最常报告预防复发(占72.2%),缓解、治疗相关及安全性结局各占67.0%。
核心结论
- 该系统文献综述提供了风湿性多肌痛和巨细胞动脉炎达标治疗策略的证据并突出知识空白,为工作组制定达标治疗推荐提供信息。
研究设计与样本
- 系统文献检索Medline、EMBASE、Cochrane Library、clinicaltrials.gov(自建库至2022年5月)及EULAR/ACR摘要数据库(2019年至2021年)。
- 筛选以英文发表、至少回答工作组提出的11个PICO问题中一个的随机对照试验和非随机干预性研究。
- 由两名研究者独立进行研究筛选、数据提取和偏倚风险评估。
- 共筛查7809篇摘要,397篇进入详细审查,最终纳入76篇文献(31项随机对照试验、8项随机对照试验亚组或探索性分析、37项非随机干预性研究)。
主要发现
- 未发现比较达标治疗策略与标准治疗的研究。
- 风湿性多肌痛随机对照试验中最常应用的治疗相关结局占90.9%,尤其是累积糖皮质激素剂量和糖皮质激素减量,其次为临床、实验室和安全性结局,各占63.3%。
- 巨细胞动脉炎随机对照试验中最常报告的结局为预防复发(72.2%),缓解、治疗相关和安全性结局各占67.0%。
局限性
- 未发现比较达标治疗策略与标准治疗的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To inform an international task force about current evidence on Treat to Target (T2T) strategies in PMR and GCA. METHODS: A systematic literature research (SLR) was conducted in Medline, EMBASE, Cochrane Library, clinicaltrials.gov from their inception date to May 2022, and in the EULAR/ACR abstract database (2019-2021). Randomised clinical trials (RCTs) and non-randomised interventional studies published in English and answering at least one of the eleven PICO questions on T2T strategies, treatment targets and outcomes, framed by the taskforce, were identified. Study selection process, data extraction and risk of bias assessment were conducted independently by two investigators. RESULTS: Of 7809 screened abstracts, 397 were selected for detailed review and 76 manuscripts were finally included (31 RCTs, eight subgroup/exploratory analyses of RCTs and 37 non-randomised interventional studies). No study comparing a T2T strategy against standard of care was identified. In PMR RCTs, the most frequently applied outcomes concerned treatment (90.9% of RCTs), particularly the cumulative glucocorticoids (GC) dose and GC tapering, followed by clinical, laboratory and safety outcomes (63.3% each). Conversely, the most commonly reported outcomes in RCTs in GCA were prevention of relapses (72.2%), remission as well as treatment-related and safety outcomes (67.0% each). CONCLUSIONS: This SLR provides evidence and highlights the knowledge gaps on T2T strategies in PMR and GCA, informing the task force developing T2T recommendations for these diseases.
引用
- Hysa E, Bond M, Ehlers L, et al. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review. Rheumatology (Oxford). 2024. PMID: 37672017. doi:10.1093/rheumatology/kead471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。